NASDAQ:AYTU Aytu BioPharma (AYTU) Stock Price, News & Analysis $1.79 -0.02 (-1.10%) Closing price 11/12/2026 04:00 PM EasternExtended Trading$1.78 -0.01 (-0.56%) As of 11/12/2026 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Aytu BioPharma Stock (NASDAQ:AYTU) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aytu BioPharma alerts:Sign Up Key Stats Today's Range$1.77▼$1.9150-Day Range$1.79▼$2.3152-Week Range$1.75▼$3.07Volume23,307 shsAverage Volume26,929 shsMarket Capitalization$19.46 millionP/E RatioN/ADividend YieldN/APrice Target$14.50Consensus RatingHold Company Overview Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on commercializing prescription medicines and other healthcare products. The company’s portfolio has primarily centered on treatments for attention-deficit/hyperactivity disorder (ADHD), along with select pediatric and primary-care products. Aytu’s ADHD products have included Adzenys XR-ODT, an extended-release orally disintegrating tablet containing amphetamine; Cotempla XR-ODT, an extended-release orally disintegrating tablet containing methylphenidate; and Evekeo, an amphetamine sulfate product. The company has also marketed pediatric nutritional products and other prescription therapies through its commercial platform. The company serves the U.S. healthcare market through relationships with prescribers, pharmacies, distributors and patients. Aytu BioPharma is headquartered in Englewood, Colorado, and has been led by Chief Executive Officer Josh Disbrow, who has been associated with the company since its early development as a specialty pharmaceutical business.AI Generated. May Contain Errors. Read More Aytu BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreAYTU MarketRank™: 2.911268158615 of 5 starsAytu BioPharma scored higher than 58% of companies evaluated by MarketBeat, and ranked 407th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingAytu BioPharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialAytu BioPharma has a consensus price target of $14.50, representing about 710.1% upside from its current price of $1.79.Amount of Analyst CoverageAytu BioPharma has only been the subject of 3 research reports in the past 90 days.Read more about Aytu BioPharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aytu BioPharma are expected to grow in the coming year, from ($0.16) to $0.14 per share.Price to Book Value per Share RatioAytu BioPharma has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aytu BioPharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.96% of the float of Aytu BioPharma has been sold short.Short Interest Ratio / Days to CoverAytu BioPharma has a short interest ratio ("days to cover") of 11.65, which indicates bearish sentiment.Change versus previous monthShort interest in Aytu BioPharma has recently decreased by 8.26%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAytu BioPharma does not currently pay a dividend.Dividend GrowthAytu BioPharma does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.60 News SentimentAytu BioPharma has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aytu BioPharma this week, compared to 2 articles on an average week.MarketBeat Follows7 people have added Aytu BioPharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aytu BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders6.14% of the stock of Aytu BioPharma is held by insiders.Percentage Held by Institutions33.49% of the stock of Aytu BioPharma is held by institutions.Read more about Aytu BioPharma's insider trading history. Receive AYTU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AYTU Stock News HeadlinesAytu BioPharma to Report Fiscal 2027 First Quarter Operational and Financial Results on November 16, 2026November 10 at 7:11 PM | finance.yahoo.comAytu BioPharma (AYTU) Expected to Post Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders. | Base Camp Trading (Ad)Aytu BioPharma no Lytham Partners Fall 2026: EXX impulsiona transiçãoSeptember 29, 2026 | br.investing.comAytu BioPharma op Lytham Partners najaar 2026: EXXUA drijft verschuivingSeptember 29, 2026 | nl.investing.comAytu BioPharma en Lytham Partners Otoño 2026: EXXUA impulsa cambioSeptember 29, 2026 | mx.investing.comAytu BioPharma, Inc. Q4 2026 Earnings Call SummarySeptember 24, 2026 | finance.yahoo.comAytu BioPharma第四财季营收超预期31%，EXXUA销售强劲推动增长September 23, 2026 | cn.investing.comSee More Headlines AYTU Stock Analysis - Frequently Asked Questions How have AYTU shares performed this year? Aytu BioPharma's stock was trading at $2.60 at the beginning of the year. Since then, AYTU shares have decreased by 31.2% and is now trading at $1.79. How were Aytu BioPharma's earnings last quarter? Aytu BioPharma Inc. (NASDAQ:AYTU) released its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.09. The business had revenue of $12.41 million for the quarter, compared to analysts' expectations of $12.05 million. Aytu BioPharma had a negative net margin of 24.76% and a negative trailing twelve-month return on equity of 56.54%. Read the conference call transcript. When did Aytu BioPharma's stock split? Aytu BioPharma's stock reverse split on the morning of Tuesday, August 29th 2017.The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Aytu BioPharma? Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aytu BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aytu BioPharma investors own include iBio (IBIO), Tesla (TSLA), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP) and NIO (NIO). Company Calendar Today11/12/2026Next Earnings (Estimated)11/16/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 AYTU's financial health is in the Yellow zone, according to TradeSmith. AYTU has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AYTU CIK1385818 Webaytubio.com Phone(720) 437-6580FaxN/AEmployees76Year FoundedN/APrice Target and Rating Average Price Target for Aytu BioPharma$14.50 High Price Target$14.50 Low Price Target$14.50 Potential Upside/Downside+710.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.25 million Net Margins-24.76% Pretax Margin-24.72% Return on Equity-56.54% Return on Assets-13.14% Debt Debt-to-Equity Ratio0.26 Current Ratio1.13 Quick Ratio1.00 Sales & Book Value Annual Sales$57.57 million Price / Sales0.34 Cash FlowN/A Price / Cash FlowN/A Book Value$3.29 per share Price / Book0.54Miscellaneous Outstanding Shares10,870,000Free Float10,201,000Market Cap$19.46 million OptionableNot Optionable Beta0.24 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:AYTU) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
